OBJECTIVES: We examined the efficacy, safety and @entity1 satisfaction of intra-articular @entity7245 ( @entity7245 ) in @entity1 with @entity626 . METHODS: One hundred @entity1 with mild to moderate @entity626 entered a randomized blind-observer trial of 6 months @entity7245 vs placebo. Primary efficacy criteria were @entity158 on walking, measured with a visual analogue scale, and the Lequesne Index. RESULTS: For @entity158 on walking, a significant difference in favour of @entity7245 was found for completed @entity1 at week 5, the end of the course of injections, and at month 6, the end of the study (P = 0.0087 and P = 0.0049, respectively). Further analysis using the Last Observation Carried Forward (LOCF) also showed a significant benefit favouring @entity7245 at month 6 (P = 0.0010). For the Lequesne Index, a significant difference in favour of @entity7245 was found at week 5 (P = 0.030) and at month 2 (P = 0.0431), but this was only of borderline significance at month 4 (P = 0.0528). @entity1 ' global assessment of efficacy favoured @entity7245 at month 6 (P = 0.012). Improvement in other secondary criteria was generally superior in the @entity7245 group compared to placebo both at week 5 and month 6. Adverse events, mainly local injection site reactions, occurred in both groups with equal frequency. CONCLUSIONS: The study demonstrated that five weekly intra-articular injections of @entity4023 (Hyalgan) were superior to placebo and well tolerated in @entity1 with @entity626 with a symptomatic benefit which persisted for 6 months.

Hyaluronic acid in the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity626 :: ('MESH:D020370', 'Disease') :: ['osteoarthritis of the knee'] @entity7245 :: ('MESH:D000592', 'Disease') :: ['hyaluronic acid', 'HA'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity4023 :: ('MESH:D006820', 'Chemical') :: ['sodium hyaluronate']
@entity626 :: (MESH:D020370,Disease) :: ['osteoarthritis of the knee']
